DNTH Dianthus Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DNTH

Price (delayed)

$11.18

Market cap

$165.66M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$17.7

Enterprise value

$9.05M

magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused ...

Highlights
DNTH's equity has soared by 139% QoQ and by 44% YoY
DNTH's debt has dropped by 98% year-on-year
Dianthus Therapeutics's quick ratio has increased by 45% YoY but it has decreased by 24% QoQ
The gross profit has declined by 21% since the previous quarter and by 21% year-on-year
The revenue has contracted by 21% from the previous quarter and by 21% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://www.magentatx.com/

Key stats

What are the main financial stats of DNTH
Market
Shares outstanding
14.82M
Market cap
$165.66M
Enterprise value
$9.05M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.24
Price to sales (P/S)
47.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.79
Earnings
Revenue
$924,000
EBIT
-$67.4M
EBITDA
-$65.92M
Free cash flow
-$41.8M
Per share
EPS
-$17.7
Free cash flow per share
-$10.7
Book value per share
$47.05
Revenue per share
$0.24
TBVPS
$49.26
Balance sheet
Total assets
$192.46M
Total liabilities
$14.08M
Debt
$670,000
Equity
$178.38M
Working capital
$178.37M
Liquidity
Debt to equity
0
Current ratio
14.64
Quick ratio
14.57
Net debt/EBITDA
2.38
Margins
EBITDA margin
-7,133.7%
Gross margin
100%
Net margin
-7,293.8%
Operating margin
-8,332.9%
Efficiency
Return on assets
-61.6%
Return on equity
-94.2%
Return on invested capital
-220.6%
Return on capital employed
-37.6%
Return on sales
-7,293.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DNTH stock price

How has the Dianthus Therapeutics stock price performed over time
Intraday
-3.7%
1 week
-1.58%
1 month
-6.6%
1 year
872.17%
YTD
2,730.38%
QTD
-18.22%

Financial performance

How have Dianthus Therapeutics's revenue and profit performed over time
Revenue
$924,000
Gross profit
$924,000
Operating income
-$77M
Net income
-$67.4M
Gross margin
100%
Net margin
-7,293.8%
DNTH's net margin is down by 42% since the previous quarter and by 27% year-on-year
The company's operating margin fell by 41% QoQ and by 39% YoY
The gross profit has declined by 21% since the previous quarter and by 21% year-on-year
The revenue has contracted by 21% from the previous quarter and by 21% YoY

Growth

What is Dianthus Therapeutics's growth rate over time

Valuation

What is Dianthus Therapeutics stock price valuation
P/E
N/A
P/B
0.24
P/S
47.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.79
The EPS rose by 29% YoY and by 22% QoQ
DNTH's equity has soared by 139% QoQ and by 44% YoY
The stock's price to book (P/B) is 88% less than its 5-year quarterly average of 2.0
The revenue has contracted by 21% from the previous quarter and by 21% YoY

Efficiency

How efficient is Dianthus Therapeutics business performance
The ROE has shrunk by 104% YoY but it has increased by 10% QoQ
DNTH's return on invested capital has dropped by 101% since the previous quarter
DNTH's return on assets has dropped by 66% year-on-year and by 4.4% since the previous quarter
The ROS fell by 42% QoQ and by 27% YoY

Dividends

What is DNTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DNTH.

Financial health

How did Dianthus Therapeutics financials performed over time
DNTH's total assets has soared by 145% QoQ and by 17% YoY
The company's total liabilities has shrunk by 65% YoY
DNTH's debt is 100% smaller than its equity
DNTH's equity has soared by 139% QoQ and by 44% YoY
The debt to equity has plunged by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.